Ozempic vs Mounjaro for type 2 diabetes
Ozempic (semaglutide) and Mounjaro (tirzepatide) are the two weekly injections most prescribed for type 2 diabetes. In a head-to-head trial Mounjaro lowered blood sugar and weight more; Ozempic has the longer record on heart and kidney outcomes. Both are brand-only.
Updated October 4, 2026
At a glance
- How it works
- Ozempic
- Activates the GLP-1 receptor
- Mounjaro
- Activates both the GIP and GLP-1 receptors
- Head-to-head result
- Ozempic
- Smaller average drops in A1c and weight
- Mounjaro
- Larger average drops in A1c and weight (SURPASS-2)
- Heart and kidney approvals
- Ozempic
- Approved to lower heart attack and stroke risk in diabetes with heart disease, and to slow kidney decline
- Mounjaro
- Check the current label; its cardiovascular trial reported in 2025
- Generic available
- Ozempic
- No
- Mounjaro
- No
Ozempic semaglutide | Mounjaro tirzepatide | |
|---|---|---|
| How it works | Activates the GLP-1 receptor | Activates both the GIP and GLP-1 receptors |
| Head-to-head result | Smaller average drops in A1c and weight | Larger average drops in A1c and weight (SURPASS-2) |
| Heart and kidney approvals | Approved to lower heart attack and stroke risk in diabetes with heart disease, and to slow kidney decline | Check the current label; its cardiovascular trial reported in 2025 |
| Generic available | No | No |
What the trials show
In SURPASS-2, people with type 2 diabetes on metformin who took tirzepatide had larger falls in A1c and body weight than those on semaglutide 1 mg. Semaglutide’s heart and kidney outcome trials led to label approvals that matter for people with established heart disease or kidney disease, and guidelines recommend a medicine with proven benefit in those situations. The best choice depends on which of those goals matters most for you.
Side effects
Both cause nausea, diarrhea, vomiting and constipation while the dose rises, and both carry the thyroid C-cell boxed warning and pancreatitis and gallbladder cautions. Both can cause low blood sugar when combined with insulin or sulfonylureas, whose doses are often reduced when either is started.
Cost
Neither has a generic, so a pharmacy’s cash price sits close to list price for both. Most commercial and Medicare plans cover at least one for type 2 diabetes, often preferring one brand; the manufacturers’ savings cards lower the copay for commercially insured patients. Medicare-negotiated prices for semaglutide take effect in January 2027.
Switching between them
People move between the two for side effects, coverage or response. Because the doses are not equivalent, the prescriber picks a starting dose on the new drug rather than converting directly, and often starts a step lower than the previous level to limit nausea.
Questions for your prescriber
- Given my heart and kidney health, which suits me better?
- Which does my plan prefer?
- Should my insulin or other diabetes medicines change when I start?
Already have a prescription?
Upload it and licensed pharmacies respond with their own cash price. You choose, and pay the pharmacy.
Read more
Sources
- NEJM, tirzepatide versus semaglutide in type 2 diabetes (SURPASS-2)
- DailyMed, FDA-approved prescribing information
- American Diabetes Association, Standards of Care in Diabetes
Written by the Script Unlock editorial team from the sources above. It is general information, not advice for you or your pet; your prescriber decides which medicine is right.
Script Unlock is a marketplace that lets licensed pharmacies quote a cash price on your prescription. It does not prescribe, dispense or sell medication, does not process patient payments, and does not give medical advice. Always follow the instructions of your prescriber and pharmacist and read the medication guide supplied with your medicine.